Androgen Deprivation Therapy in High-Risk Prostate Cancer

被引：0
作者：
Buyyounouski, Mark K. [1 ]
机构：
[1] Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA
来源：
ONCOLOGY-NEW YORK | 2010年 / 24卷 / 09期
关键词：
RADIOTHERAPY;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：806 / 809
页数：2
相关论文
共 50 条
  • [21] Assessing the Optimum Use of Androgen-Deprivation Therapy in High-Risk Prostate Cancer Patients Undergoing External Beam Radiation Therapy
    Ludwig, Michelle S.
    Kuban, Deborah A.
    Strom, Sara S.
    Du, Xianglin L.
    Lopez, David S.
    Yamal, Jose-Miguel
    AMERICAN JOURNAL OF MENS HEALTH, 2017, 11 (01) : 73 - 81
  • [22] Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial
    Fizazi, Karim
    Faivre, Laura
    Lesaunier, Francois
    Delva, Remy
    Gravis, Gwenaelle
    Rolland, Frederic
    Priou, Frank
    Ferrero, Jean-Marc
    Houede, Nadine
    Mourey, Loic
    Theodore, Cnristine
    Krakowski, Ivan
    Berdah, Jean-Francois
    Baciuchka, Marjorie
    Laguerre, Brigitte
    Flechon, Aude
    Ravaud, Alain
    Cojean-Zelek, Isabelle
    Oudard, Stephane
    Labourey, Jean-Luc
    Chinet-Charrot, Paule
    Legouffe, Eric
    Lagrange, Jean-Leon
    Linassier, Claude
    Deplanque, Gael
    Beuzeboc, Philippe
    Davin, Jean-Louis
    Martin, Anne-Laure
    Habibian, Muriel
    Laplanche, Agnes
    Culine, Stephane
    LANCET ONCOLOGY, 2015, 16 (07) : 787 - 794
  • [23] High-dose-rate interstitial brachytherapy in combination with androgen deprivation therapy for prostate cancer Are high-risk patients good candidates?
    Yoshida, Ken
    Yamazaki, Hideya
    Takenaka, Tadashi
    Kotsuma, Tadayuki
    Yoshida, Mineo
    Masui, Koji
    Yoshioka, Yasuo
    Narumi, Yoshifumi
    Oka, Toshitsugu
    Tanaka, Eiichi
    STRAHLENTHERAPIE UND ONKOLOGIE, 2014, 190 (11) : 1015 - 1020
  • [24] Comparison of neoadjuvant vs concurrent/adjuvant androgen deprivation in men with high-risk prostate cancer receiving definitive radiation therapy
    Lee, Anna
    Becker, Daniel J.
    Lederman, Ariel J.
    Osborn, Virginia W.
    Shao, Meng S.
    Wong, Andrew T.
    Schwartz, David
    Schreiber, David
    TUMORI, 2017, 103 (04) : 387 - 393
  • [25] Duration of androgen deprivation with radio-therapy for high-risk or locally advanced prostate cancer: A network meta-analysis
    Petrelli, Fausto
    De Stefani, Agostina
    Vavassori, Ivano
    Motta, Federica
    Luciani, Andrea
    Trevisan, Francesca
    TUMORI JOURNAL, 2023, 109 (04): : 424 - 429
  • [26] Avoiding Androgen Deprivation Therapy in Men With High-risk Prostate Cancer: The Role of Radical Prostatectomy as Initial Treatment EDITORIAL COMMENT
    Boorjian, Stephen A.
    Blute, Michael L.
    UROLOGY, 2011, 77 (04) : 950 - 951
  • [27] Can we avoid high levels of dose escalation for high-risk prostate cancer in the setting of androgen deprivation?
    Shakespeare, Thomas P.
    Wilcox, Shea W.
    Aherne, Noel J.
    ONCOTARGETS AND THERAPY, 2016, 9 : 2819 - 2824
  • [28] Short-course androgen deprivation therapy and the risk of death from high-risk prostate cancer in men undergoing external beam radiation therapy and brachytherapy
    Raldow, Ann C.
    Zhang, Danjie
    Chen, Ming-Hui
    Braccioforte, Michelle H.
    Moran, Brian J.
    D'Amico, Anthony V.
    BRACHYTHERAPY, 2015, 14 (06) : 781 - 787
  • [29] CONCURRENT ANDROGEN DEPRIVATION THERAPY DURING SALVAGE PROSTATE RADIOTHERAPY IMPROVES TREATMENT OUTCOMES IN HIGH-RISK PATIENTS
    Soto, Daniel E.
    Passarelli, Michael N.
    Daignault, Stephanie
    Sandler, Howard M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (03): : 1227 - 1232
  • [30] Changes in Magnetic Resonance Imaging Radiomic Features in Response to Androgen Deprivation Therapy in Patients with Intermediate- and High-risk Prostate Cancer
    Tharmalingam, H.
    Tsang, Y. M.
    Alonzi, R.
    Beasley, W.
    Taylor, N. J.
    McWilliam, A.
    Padhani, A.
    Choudhury, A.
    Hoskin, P. J.
    CLINICAL ONCOLOGY, 2022, 34 (06) : E246 - E253
12345